Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 11,000 shares, a decrease of 24.7% from the December 31st total of 14,600 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 1.6 days.
Incannex Healthcare Stock Down 0.9 %
Incannex Healthcare stock opened at $3.41 on Monday. Incannex Healthcare has a twelve month low of $2.60 and a twelve month high of $90.00. The stock's fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.98.
Get Incannex Healthcare alerts:Institutional Trading of Incannex Healthcare
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare during the first quarter worth $378,000. FNY Investment Advisers LLC acquired a new position in shares of Incannex Healthcare during the third quarter worth $69,000. Finally, UBS Group AG acquired a new position in shares of Incannex Healthcare during the first quarter worth $25,000. Hedge funds and other institutional investors own 0.07% of the company's stock.
About Incannex Healthcare
(Get Rating)Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Featured Articles
- Get a free copy of the StockNews.com research report on Incannex Healthcare (IXHL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.